Although previous studies have demonstrated that the electrophysiologic effects of many antiarrhythmic agents can be reversed by catecholamines, the susceptibility of amiodarone to such rever· sal is unknown. The objective of this study was to compare the relative degree of reversal of the electrophysiologic effects of quinidine and amiodarone by epinephrine infusions that result in plasma epinephrine levels similar to those achieved during various physiologic stresses. Twenty-nine patients who had inducible sustained monomorphic ventricular tachycardia and underwent electropharmacologic testing with quinidine and amiodarone were enrolled in the study. The variables measured before and during an epinephrine infusion (25 or 50 ng/kg per min) included the sinus cycle length, mean arterial pressure, QT interval and effective refractory period at drive train cycle lengths of 600 and 400 ms.
Although previous studies have demonstrated that the electrophysiologic effects of many antiarrhythmic agents can be reversed by catecholamines, the susceptibility of amiodarone to such rever· sal is unknown. The objective of this study was to compare the relative degree of reversal of the electrophysiologic effects of quinidine and amiodarone by epinephrine infusions that result in plasma epinephrine levels similar to those achieved during various physiologic stresses. Twenty-nine patients who had inducible sustained monomorphic ventricular tachycardia and underwent electropharmacologic testing with quinidine and amiodarone were enrolled in the study. The variables measured before and during an epinephrine infusion (25 or 50 ng/kg per min) included the sinus cycle length, mean arterial pressure, QT interval and effective refractory period at drive train cycle lengths of 600 and 400 ms.
The effective refractory period measured at a drive train cycle length of 600 ms shortened less during amiodarone therapy (2 ± 2%) than during quinidine therapy (6 ± 4%) or than in the baseline state (6 ± 4%; p < 0.01). Similar results were obtained during evaluation of the effective refractory period at a cycle length of 400 ms. Epinephrine infusion, at both 25 and 50 nglkg per min, completely reversed the effects of quinidine and partially Antiarrhythmic therapy guided by serial electrophysiologic studies has become a standard approach to the management of malignant ventricular arrhythmias (1). The suppression of inducible ventricular tachycardia by an antiarrhythmic agent is generally predictive of an excellent long-term response (2, 3) . However, several studies have reported recurrences of ventricular tachycardia in up to 32% of patients in whom it was suppressed by an antiarrhythmic agent during electrophysiologic testing (4) (5) (6) . Recent studies (7) (8) (9) (10) (11) (12) (13) have suggested that sympathetic activation may reverse or antagonize the effects of antiarrhythmic agents, and this phenomenon may be reversed the effects of amiodarone on the effective refractory period. The effects of epinephrine on the sinus cycle length and QT interval were similar in the baseline state and in conjunction with quinidine and amiodarone. Twenty-four patients underwent programmed ventricular stimulation during amiodarone therapy alone and in conjunction with either a 25-or a 50-ng/kg per min infusion of epinephrine. None of the five patients whose ventricular tachycardia was suppressed by amiodarone had sustained ventricular tachycardia induced during an epinephrine infusion. The ventricular tachycardia cycle length in patients with persis· tently inducible ventricular tachycardia also did not change after an epinephrine infusion. No patient receiving long-term amio· darone therapy has had a recurrence of ventricular tachycardia during a mean follow-up interval of 9 ± 4 months.
The results of this study demonstrate that amiodarone is more resistant than quinidine to reversal of its electrophysiologic effects by epinephrine. This resistance may be due to the beta-adrenergic blocking properties of amiodarone and may explain, at least in part, the drug's unique long-term effectiveness in treating malig· nant ventricular arrhythmias. (JAm Coli Cardio/1992; 19:347-52) one reason why electropharmacologic testing does not always accurately predict the long-term response to a drug. Although the electrophysiologic effects of most antiarrhythmic agents appear to be susceptible to reversal by catecholamines (7) (8) (9) (10) (11) (12) , it is possible that drugs such as amiodarone, which have beta-adrenergic blocking properties (14) (15) (16) , are resistant to the antagonistic effects of sympathetic activation. However, the susceptibility of amiodarone to reversal of its effects by sympathetic activation is unknown.
The objective of this study was to compare the relative degree of reversal of the electrophysiologic effects of quinidine and amiodarone by epinephrine infusions that result in plasma catecholamine concentrations similar to those achieved during a variety of physiologic stresses.
Methods
Study patients. The subjects of this study were 29 patients with inducible sustained monomorphic ventricular tachycardia who underwent electropharmacologic testing with both quinidine and amiodarone. The presenting arrhythmia was sustained monomorphic ventricular tachycardia in 16 patients, nonsustained ventricular tachycardia in 5, syncope in 5 and ventricular fibrillation in 3. Twenty-five patients were men and 4 were women. Their mean age was 64 ± 9 years. Twenty-eight patients had coronary artery disease and had sustained a myocardial infarction at least 6 months before their evaluation. One patient had a nonischemic dilated cardiomyopathy. The mean left ventricular ejection fraction was 0.32 ± 0.11.
Electrophysiologic testing. Electrophysiologic tests were performed with patients in the fasting state at least 5 halflives after discontinuation of all antiarrhythmic drugs including beta-adrenergic blocking agents. The study protocol was approved by the Human Research Committee at the University of Michigan and informed consent was obtained from each patient. Quadripolar electrode catheters were inserted into a femoral vein and positioned at the high right atrium, across the tricuspid valve to record a His bundle electrogram, and at the apex of the right ventricle. A 5F cannula was inserted into a femoral artery for blood pressure monitoring. Leads V 1 , I and Ill, the intracardiac electrograms and blood pressure were recorded at a paper speed of 25 mm/s with use of a Siemens-Elema Mingograf 7 recorder. Programmed stimulation was performed with a programmable stimulator (Bloom Associates) with stimuli that had a duration of 2 ms and a current intensity of twice diastolic threshold.
Programmed ventricular stimulation was performed with up to 3 extrastimuli using 8-beat basic drive trains at cycle lengths of 600, 400 and 350 ms. If sustained monomorphic ventricular tachycardia was not induced at the cardiac apex, programmed stimulation with an identical protocol was repeated at the right ventricular septum or outflow tract. Sustained ventricular tachycardia was defined as ventricular tachycardia > 30 s in duration or requiring cardioversion for termination because of hemodynamic instability.
All patients also underwent electrophysiologic testing after treatment with quinidine and amiodarone. Follow-up testing during quinidine therapy was performed :2::48 h after initiation of treatment with quinidine gluconate, 486 to 648 mg three times/day. The follow-up electrophysiologic test was performed <2 h before the next scheduled dose. The mean plasma quinidine concentration at the time of follow-up electrophysiologic testing was 2.9 ± 0.8 mg/liter. Each patient still had inducible sustained monomorphic ventricular tachycardia during treatment with quinidine and was then treated with amiodarone. Follow-up electrophysiologic testing during amiodarone therapy was performed 9 to 10 days after initiation of treatment with amiodarone, 1,800 mg/day in three divided doses. The mean plasma amiodarone concentration at the time of the electrophysiologic test was 2 ± 0.43 mg/liter. The programmed stimulation protocol during follow-up electrophysiologic testing was identical to the protocol used during the baseline electrophysiologic test. Epinephrine infusion. The electrophysiologic effects of epinephrine were determined in the baseline state and during treatment with quinidine and amiodarone. The variables measured before and during the epinephrine infusion included the sinus cycle length, mean blood pressure, QT interval and ventricular effective refractory period at drive train cycle lengths of 600 and 400 ms. The QT interval was determined (to the nearest 10 ms) from an electrocardiogram (ECG) of the six limb leads recorded at a paper speed of 50 or 100 mm/s during atrial pacing at a cycle length of 500 ms. The ventricular refractory period was determined by introducing an extrastimulus 290 ms after an 8-beat drive train that was followed by a 3-s pause. The coupling interval of the extrastimulus was progressively decreased in 10-ms steps until it failed to capture. The coupling interval was then increased in 2-ms steps until capture occurred. The effective refractory period was defined as the longest coupling interval at which the extrastimulus failed to capture. The effective refractory period was repeated to assure reproducibility to within 2 ms. After the baseline variables were obtained, epinephrine was infused at a dose of 25 ng/kg per min (17 patients) or 50 ng/kg per min (12 patients). Previous studies have shown that a steady state epinephrine level is achieved after 10 min of a constant infusion (17, 18) . Therefore, after at least 14 min of epinephrine infusion, the electrophysiologic variables were remeasured. All patients except those who required cardioversion for termination of ventricular tachycardia also had programmed ventricular stimulation repeated during treatment with amiodarone after an epinephrine infusion.
An infusion rate of 25 ng/kg per min has been demonstrated to result in a mean plasma epinephrine concentration of 863 ± 226 pg/ml, which is similar to that achieved endogenously in response to submaximal exercise, cigarette smoking, public speaking and surgery (19) (20) (21) (22) . An infusion rate of 50 ng/kg per min has been demonstrated to result in a mean plasma epinephrine concentration of 1,374 ± 477 pg/ml, which is similar to that achieved during maximal exercise, myocardial infarction, diabetic ketoacidosis and severe hypoglycemia (19) (20) (21) (22) .
Statistical analysis. All data are expressed as mean values ± 1 SD. The effects of epinephrine were assessed using a paired t test. The relative effects of epinephrine in the baseline state and during treatment with quinidine and amiodarone were compared by a repeated measures analysis of variance. Multiple comparisons were performed with Fisher's least significant difference procedure (23) . A p value <0.05 was considered significant.
Results
Effects on arterial pressure. The mean baseline arterial pressure was 94 ± 18 mm Hg. Neither quinidine nor amiodarone had any effect on this value, which also did not change during epinephrine infusions of 25 or 50 ng/kg per min. Effects on sinus cycle length and QT interval. Quinidine had no effect on the sinus cycle length, whereas amiodarone lengthened it by a mean of28 ± 26% (p < 0.01, Table 1 ). The 25 ng!kg per min infusion of epinephrine shortened the sinus cycle length by a mean of 9 ± 8% during the baseline electrophysiologic test (p < 0.01) compared with a shortening of 14 ± 7% during treatment with quinidine (p < 0.01) and 7 ± 6% during treatment with amiodarone (p = 0.02). The effect of epinephrine on the sinus cycle length tended to be less in the presence of amiodarone than in the presence of quinidine (p = 0.07, Table 2 ). The effects of the 50-ng/kg per min infusion and the 25-ng/kg per min infusion of epinephrine were similar. The relative effects of the 50-ng/kg per min infusion of epinephrine were similar in the baseline state and in the presence of quinidine and amiodarone (p = 0.16, Table   2 ).
Both quinidine and amiodarone increased the QT inter-
val: quinidine by 11 ± 14% (p < 0.01) and amiodarone by 34 ± 12% (p < 0.01). The 25-ng/kg per min infusion of epinephrine shortened the QT interval by a mean of 5 ± 6% during the baseline electrophysiologic test (p < 0.01) versus a shortening of 4 ± 3% (p < 0.01) during treatment with quinidine and 4 ± 4% (p < 0.01) during treatment with amiodarone. The relative effects of epinephrine were similar Values are expressed as mean values ± SD. ! QT = decrease in QT interval during atrial pacing at 500 ms; ! SCL = decrease in sinus cycle length; other abbreviations as in Table I .
in the baseline state and in the presence of quinidine and amiodarone (p = 0.63 , Table 2 ). The effects of the 50-ng/kg per min infusion of epinephrine were similar to those of the 25-ng/kg per min infusion. The relative effects of the 50-ng/kg per min infusion of epinephrine were also similar in the baseline state and in the presence of quinidine and amiodarone (p = 0.33, Table 2 ).
Effects on the ventricular effective refractory period. The ventricular effective refractory period measured at a drive train cycle length of 600 ms increased by 12 ± 6% during treatment with quinidine (p < 0.01) and by 12 ± 4% during treatment with amiodarone (p < 0.01, Table 3 ). Epinephrine, at an infusion rate of 25 ng!kg per min, shortened the effective refractory period by 6 ± 4% in the baseline state (p < 0.01), by 6 ± 4% during treatment with quinidine (p < 0.01) and by 2 ± 2% during treatment with amiodarone (p < 0.01). Epinephrine completely reversed the effects of quinidine on the effective refractory period and partially reversed those of amiodarone. The effective refractory period measured during quinidine therapy together with an epinephrine infusion was unchanged from the baseline state (p = 0.08). However, during amiodarone therapy the effective refractory period remained significantly longer during an epinephrine infusion than in the baseline state (p < 0.01). The effect of epinephrine in the presence of amiodarone was significantly less than in the baseline state or in the presence of quinidine (p < 0.01, Table 4 ). Similar results were obtained during evaluation of the effective refractory period at a cycle length of 400 ms.
The electrophysiologic effects of the 50-ng/kg per min epinephrine infusion in the baseline state and during quinidine and amiodarone therapy were similar to those of the 25-ng/kg per min epinephrine infusion. Epinephrine shortened the effective refractory period and resulted in complete reversal of the effects of quinidine and partial reversal of the effects of amiodarone. Epinephrine, at an infusion rate of and 600 ms, respectively; other abbreviations as in Table I .
50-ng/kg per min, had similar electrophysiologic effects in the baseline state and during treatment with quinidine and amiodarone ( Table 4) . Effects of epinephrine on induction of ventricular tachycardia during amiodarone therapy. Consistent with the design of this study, each patient had inducible sustained monomorphic ventricular tachycardia in the baseline state and during treatment with quinidine. Follow-up programmed ventricular stimulation during amiodarone therapy demonstrated no inducible ventricular tachycardia in 5 patients, nonsustained ventricular tachycardia in 1 patient (26 beats) and sustained monomorphic ventricular tachycardia in 23 patients. Twenty-four patients had programmed ventricular stimulation repeated during either a 25-(14 patients) or a 50-(10 patients) ng/kg per min infusion of epinephrine. Four of these patients had no inducible ventricular tachycardia and one patient had nonsustained ventricular tachycardia induced during amiodarone therapy. None of these patients had inducible ventricular tachycardia during the epinephrine infusion (25 ng/kg per min in four patients and 50 ng/kg per min in one patient). Among the remaining 19 patients who had persistently inducible sustained monomorphic ventricular tachycardia during amiodarone therapy, ventricular tachycardia was no longer inducible in one patient after a 25-ng/kg per min infusion of epinephrine. The ventricular tachycardia induced in the remaining 18 patients during either a 25-(9 patients) or a 50-(9 patients) ng/kg per min infusion of epinephrine had a similar configuration in 14 patients and a different configuration in 4. The mean tachycardia cycle length was not significantly different before (395 ± 74 ms) and during (378 ± 73 ms) the epinephrine infusion (p = 0.2). FoUow-up. Long-term therapy was guided by the response to amiodarone during follow-up electrophysiologic testing. Five patients who had no inducible ventricular tachycardia or had inducible nonsustained ventricular tachycardia were treated with amiodarone, 400 mg/day. Eight patients who had hemodynamically unstable ventricular tachycardia induced underwent placement of an implantab1e defibrillator. The remaining 16 patients had hemodynamically stable ventricular tachycardia induced and were treated with amiodarone, 400 mg/day. During a mean follow-up period of 9 ± 4 months, no patient who received long-term treatment with amiodarone has had recurrent ventricular tachycardia or sudden cardiac death.
Discussion
The results of this study demonstrate that amiodarone is more resistant than quinidine to reversal of its electrophysiologic effects by epinephrine infused at rates that result in plasma epinephrine concentrations similar to those that occur endogenously during a variety of physiologic and pathologic stresses. Epinephrine resulted in less shortening of ventricular refractoriness during treatment with amiodarone than during treatment with quinidine. Furthermore, in no patient were the antiarrhythmic effects of amiodarone reversed by epinephrine.
Differential reversal of the electrophysiologic effects of quinidine and amiodarone. Consistent with its known electrophysiologic effects, quinidine prolonged the QT interval and increased ventricular refractoriness. Epinephrine at both low (25-ng/kg per min) and high (50-ng/kg per min) infusion rates partially or completely reversed the effects of quinidine on the QT interval and refractoriness. The ventricular effective refractory periods during therapy with quinidine in conjunction with an epinephrine infusion were no different from those in the baseline drug-free state. Amiodarone also prolonged the QT interval and refractoriness. However, low and high dose epinephrine infusions attenuated but did not completely reverse the effects of amiodarone. The effective refractory period during therapy with amiodarone, in contrast to that during quinidine therapy, remained significantly longer during an epinephrine infusion than that in the drug-free state.
The differential antagonism of the electrophysiologic effects of quinidine and amiodarone indicates a relative resistance of amiodarone to the effects of epinephrine. At an infusion rate of 25 ng/kg per min of epinephrine the degree of shortening of the effective refractory period was less during therapy with amiodarone than in the baseline drug-free state or during therapy with quinidine. This differential effect persisted but did not reach statistical significance at an epinephrine infusion rate of 50 ng/kg per min. Thus, the resistance of amiodarone to reversal by epinephrine appears to be dose dependent.
Effects of epinephrine on the inducibility of ventricular tachycardia. The results of electropharmacologic testing during amiodarone therapy were not altered after an epinephrine infusion. No patient whose sustained ventricular tachycardia was suppressed during amiodarone therapy had this arrhythmia induced during an epinephrine infusion, and no patient who had hemodynamically stable ventricular tachycardia induced during amiodarone therapy had hemodynamically unstable ventricular tachycardia induced after infusion of epinephrine. None of the 22 patients treated long term with amiodarone have had recurrent ventricular tachycardia during follow-up. These findings suggest that the antiarrhythmic actions of amiodarone, like its electrophysiologic effects, are resistant to reversal by sympathetic activation.
The resistance of amiodarone to reversal of its antiarrhythmic effects by epinephrine is in marked contrast to the findings of previous studies that have evaluated the effects of type I antiarrhythmic agents in conjunction with catecholamine infusions. Morady et al. (11) demonstrated that the results of electropharmacologic testing in patients with inducible sustained momorphic ventricular tachycardia were significantly altered by epinephrine in 50% of patients treated with quinidine. Similarly, Jazayeri et al. (12) reported that isoproterenol reversed the therapeutic effects of type I antiarrhythmic agents in 59% of patients with ventricular arrhythmias.
CALKINS ET AL.
REVERSAL OF DRUG EFFECTS BY EPINEPHRINE
Results of previous studies. No previous study has evaluated the electrophysiologic effects of catecholamines in conjunction with amiodarone therapy in patients with ventricular tachycardia or has compared the relative effects of catecholamines on the actions of two antiarrhythmic agents. Brugada et al. (13) evaluated the effect of isoproterenol in patients with atrioventricular (A V) reciprocating tachycardia in the baseline state and during amiodarone therapy and reported similar electrophysiologic and antiarrhythmic effects of isoproterenol in the two groups. They concluded that amiodarone had minimal beta-blocking properties, and that amiodarone's antiarrhythmic actions were susceptible to reversal by catecholamines. This study differs from the present study in several important respects, which may explain the discrepant conclusions. First, in the study by Brugada et al. (13) , different patients were studied in the drug-free state and during amiodarone therapy. Therefore, patients did not serve as their own controls. Second, their patients were treated with 200 mg/day of amiodarone whereas our study patients were tested after receiving a loading dose of 1,800 mg/day of amiodarone for 9 to 10 days. Amiodarone's beta-blocking properties may be dose dependent. Third, Brugada et al. (13) evaluated the effect of isoproterenol titrated to achieve a 20% increase in heart rate. The physiologic relevance of this dose of isoproterenol is unknown. In our study, the effects of physiologic doses of epinephrine were evaluated. Finally, Brugada et al. (13) evaluated the effects of amiodarone therapy in patients with A V reciprocating tachycardia whereas the patients in our study had ventricular tachycardia.
Several prior studies have reported that the electrophysiologic effects of type I antiarrhythmic agents can be antagonized by catecholamines in patients with supraventricular or ventricular arrhythmias. Morady et al. (11) demonstrated that physiologic levels of epinephrine completely or partially reversed the effects of quinidine. Other investigators have reported reversal of type I antiarrhythmic drug effects by catecholamines in patients with A V node reentrant tachycardia (10) or A V reciprocating tachycardia (7 ,8) . Antiarrhythmic drugs shown to be susceptible to reversal of their electrophysiologic actions by catecholamines include verapamil (9), quinidine (7,11), encainide (10) and fiecainide (8) . Thus, amiodarone's resistance to reversal of its antiarrhythmic actions is unique among antiarrhythmic agents.
Mechanism of differential antagonism. The precise mechanism of amiodarone's resistance to reversal of its electrophysiologic and antiarrhythmic effects by epinephrine cannot be determined from this study. However, this resistance may result from amiodarone's beta-blocking actions (14-16). Kadish et al. (15) recently demonstrated that amiodarone has beta-blocking effects in humans that are present within 2 days of initiation of oral amiodarone therapy. This mechanism is also consistent with a study by Manolis et al. (8) , who demonstrated that propranolol can prevent reversal of the electrophysiologic effects of fiecainide by isoproterenol. Clinical significance. Although previous studies (2) (3) (4) (5) (6) have demonstrated that the suppression of inducible ventricular tachycardia during serial electrophysiologic testing is generally predictive of an excellent long-term response to an antiarrhythmic agent, ventricular tachycardia may recur in up to 32% of patients. This may be because electrophysiologic testing, which is generally performed in the rest state, does not evaluate the effects of antiarrhythmic agents after changes in autonomic tone. Previous studies (7) (8) (9) (10) (11) (12) (13) have demonstrated that sympathetic activation may reverse the electrophysiologic effects of type I antiarrhythmic agents. We have demonstrated that amiodarone is more resistant than is quinidine to reversal of its electrophysiologic effects by epinephrine. The relative resistance of amiodarone to sympathetic activation may explain, at least in part, amiodarone's apparent unique long-term effectiveness in treating malignant ventricular arrhythmias (3 ,24,25) . The results of this study, together with the results of previous studies (ll, 12), suggest that the long-term predictive accuracy of electropharmacologic therapy may be improved by routinely evaluating the efficacy of antiarrhythmic agents in the baseline state and during a catecholamine infusion. Antiarrhythmic agents whose antiarrhythmic actions are reversed during a catecholamine infusion may be more likely to be associated with a recurrence of tachycardia during follow-up, as compared with antiarrhythmic agents whose effects are maintained during a catecholamine infusion. It is possible that the long-term efficacy of antiarrhythmic agents whose effects are demonstrated to be susceptible to reversal by increased sympathetic tone may be improved by concomitant therapy with beta-blockers.
